Form 4 for HAE HAEMONETICS CORP

Accepted 2023-05-17 00:00:00 ET · period of report 2023-05-15 · accession 0001127602-23-015931 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-05-17	2023-05-16	HAE	Basil Michelle L	EVP, GC	F - Tax	$89.21	-446	36.0K	-1%	-$39.8K
D	2023-05-17	2023-05-15	HAE	Basil Michelle L	EVP, GC	A - Grant	—	+4,205	36.5K	+13%	—
D	2023-05-17	2023-05-15	HAE	Basil Michelle L	EVP, GC	A - Grant	$0.00	+9,502	9,502	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-05-16	F	D	446	$89.21	36,010	D	—	—	(F4) Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I. (F3) This number includes unvested RSUs previously reported.
2	Common	Common Stock	2023-05-15	A	A	4,205	—	36,456	D	—	—	(F1) The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. (F2) Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. (F3) This number includes unvested RSUs previously reported.
3	Derivative	Non-qualified Stock Option (Right to Buy)	2023-05-15	A	A	9,502	$0.00	9,502	D	$89.16 · — to 2030-05-15	9,502 Common Stock	(F5) Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.